Anti-atopic dermatitis effects of dictamni cortex: Studies on in vitro and in vivo experimental models
Anti-atopic dermatitis effects of dictamni cortex: Studies on in vitro and in vivo experimental models
复制标题
白皮皮质的抗特应性皮炎作用：体外和体内实验模型的研究
DOI：
10.1016/j.phymed.2020.153453
复制
发表时间：
2021-01-12
期刊：
影响因子：
7.9
通讯作者：
Lin, Zhi-Xiu
中科院分区：
文献类型：
--
作者：
Chen, Yunlong;Xian, Yan-Fang;Lin, Zhi-Xiu
背景资料：白藓皮（DC）是一种具有祛风止痒作用的中草药，是治疗特应性皮炎（AD）最常用的单味药，其使用率高达AD所有草药处方的12.68%。目的：本研究旨在评价白藓皮提取物（DCE）的抗AD作用方法：用200 μ l 0.5%二硝基氯苯（DNCB）致敏Balb/c雌性小鼠3d，观察其对AD样小鼠的作用。致敏后，小鼠背部皮肤用1%DNCB 200 μ l攻击，每3天在每只耳朵上也用1%DNCB 20 μ l攻击，从第14天至第29天每天经口灌胃给予DCE（0.6，1.2和2.4g/kg），连续16天。实验结束后，计算AD小鼠的临床评分，评价DCE的治疗效果，并采集小鼠血清、耳及背部皮肤进行机制研究。用抗原诱导的RBL-2H3细胞系评价了DCE的抗过敏活性。测定所选细胞因子、趋化因子和β-氨基己糖苷酶的释放，以确定DCE的抗过敏活性。此外，还通过对细胞内Ca2+水平、MAPK和林恩磷酸化的研究，进一步揭示其抗过敏的分子机制。结果表明，DCE可通过抑制肥大细胞浸润，抑制Th2相关细胞因子（IL-4）和促炎细胞因子的产生，明显改善AD样小鼠的AD样症状（TNF-α），并通过抑制MAPK和NF-κ B途径增强聚丝蛋白的蛋白表达。DCE通过降低肥大细胞内Ca~（2+）水平和灭活林恩、Syk和PLC γ s抑制肥大细胞脱颗粒，提示DCE可调节肥大细胞介导的变态反应。结论：DCE具有较强的抗变态反应作用，为DC治疗AD提供了科学依据。
Background: Dictamni Cortex (DC), a Chinese herbal medicine with wind dispelling and itchiness relieving effects, is the most popular single herb prescribed for the treatment of atopic dermatitis (AD), as it is used in up to 12.68% of all herbal prescriptions for AD.Purpose: The present study aimed to evaluate the anti-AD effect of Dictamni Cortex extract (DCE) and elucidate the underlying molecular mechanisms of its action using the 1-chloro-2,4-dinitrobenzene (DNCB)-induced AD-like mouse model and a relevant in vitro experimental model.Methods: Female Balb/c mice were sensitized with 200 mu l 0.5% DNCB for three days. After sensitization, mice were challenged with 200 mu l 1% DNCB on the same dorsal skin and also 20 mu l 1% DNCB on each ear every 3 days, and orally administrated by gavage with DCE (0.6, 1.2 and 2.4 g/kg) daily from day 14 to day 29 for 16 consecutive days. At the end of experiment, the clinical scores for AD on the mice were calculated to evaluate the therapeutic effect of DCE; and serum, ears and dorsal skin of the mice were collected for mechanistic study. The anti-allergic activity of DCE was also evaluated using antigen-induced RBL-2H3 cell line. The release of selected cytokines, chemokines and beta-hexosaminidase was measured to determine the anti-allergic activity of DCE. In addition, intracellular Ca2+ level, MAPKs and Lyn phosphorylations were further investigated to reveal its anti-allergic molecular mechanisms.Results: Our results demonstrated that DCE could markedly improve the AD-like symptoms in AD-like mice by inhibiting the mast cell infiltration, suppressing the production of Th2-associated cytokine (IL-4) and pro-inflammatory cytokines (TNF-alpha), and enhancing the protein expression of filaggrin through inhibition of the MAPKs and NF-kappa B pathways. Moreover, DCE suppressed mast cell degranulation through decreasing the intracellular Ca2+ level and inactivation of Lyn, Syk and PLC gamma s, suggesting DCE could regulate mast-cell-mediated allergic response.Conclusion: Our experimental results unambiguously indicate that DCE possesses potent anti-allergic effect, and help place the application of DC for the treatment of AD on a scientific footing.